Novartis AG ADR (NVS)vsOmniAb Inc. (OABI)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
OABI
OmniAb Inc.
$1.36
-2.86%
HEALTHCARE · Cap: $208.49M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 303007% more annual revenue ($56.58B vs $18.67M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
OABI
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for OABI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : OABI
The strongest argument for OABI centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : OABI
The primary concerns for OABI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while OABI is a value play — different risk/reward profiles.
OABI carries more volatility with a beta of 0.87 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 27/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →OmniAb Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
OmniAb Inc. is a pioneering biotechnology firm focused on the creation of fully human therapeutic antibodies through its cutting-edge OmniAb platform. This unique technology facilitates the rapid discovery and refinement of high-efficacy therapeutics to tackle a diverse range of diseases. By fostering strategic partnerships and collaborations, OmniAb strives to expedite drug development and broaden access to innovative therapies. With an experienced leadership team and a strong product pipeline, the company is well-positioned to seize expanding opportunities within the biopharmaceutical landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?